Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;39(5):791-797.
doi: 10.1007/s10096-019-03769-8.

Diagnostic and medical needs for therapeutic drug monitoring of antibiotics

Claude Mabilat  1 , Marie Francoise Gros  2 , David Nicolau  3 , Johan W Mouton  4 , Julien Textoris  2 , Jason A Roberts  5   6   7 , Menino O Cotta  5   6   7 , Alex van Belkum  8 , Isabelle Caniaux  2
Affiliations
Review

Diagnostic and medical needs for therapeutic drug monitoring of antibiotics

Claude Mabilat et al. Eur J Clin Microbiol Infect Dis. 2020 May.

Abstract

Therapeutic drug monitoring (TDM) of antibiotics has been practiced for more than half a century, but it is still not widely applied for infected patients. It has a traditional focus on limiting toxicity of specific classes of antibiotics such as aminoglycosides and vancomycin. With more patients in critical care with higher levels of sickness severity and immunosuppression as well as an increasingly obese and ageing population, an increasing risk of suboptimal antibiotic exposure continues to escalate. As such, the value of TDM continues to expand, especially for beta-lactams which constitute the most frequently used antibiotic class. To date, the minimum inhibitory concentration (MIC) of infectious microbes rather than classification in terms of susceptible and resistant can be reported. In parallel, increasingly sophisticated TDM technology is becoming available ensuring that TDM is feasible and can deliver personalized antibiotic dosing schemes. There is an obvious need for extensive studies that will quantify the improvements in clinical outcome of individual TDM-guided dosing. We suggest that a broad diagnostic and medical investigation of the TDM arena, including market analyses and analytical technology assessment, is a current priority.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kirkman AC. A review of bacteriological sensitivity tests and a capillary tube method for the determination of antibiotic levels in the body fluids. Cent Afr J Med. 1956;2(10):367–369. - PubMed
    1. Begg EJ, Barclay ML, Kirkpatrick CJ. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol. 1999;47(1):23–30. doi: 10.1046/j.1365-2125.1999.00850.x. - DOI - PMC - PubMed
    1. Begg EJ, Barclay ML, Kirkpatrick CJ. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol. 2001;52(Suppl 1):35S–43S. doi: 10.1046/j.1365-2125.2001.00377.x. - DOI - PMC - PubMed
    1. Wenk M, Vozeh S, Follath F. Serum level monitoring of antibacterial drugs. A review. Clin Pharmacokinet. 1984;9(6):475–492. doi: 10.2165/00003088-198409060-00001. - DOI - PubMed
    1. Mattioli F, Fucile C, Del Bono V, Marini V, Parisini A, Molin A, Zuccoli ML, Milano G, Danesi R, Marchese A, Polillo M, Viscoli C, Pelosi P, Martelli A, Di Paolo A. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. Eur J Clin Pharmacol. 2016;72(7):839–848. doi: 10.1007/s00228-016-2053-x. - DOI - PubMed

Substances